Getinge AB (publ) - GNGBY Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$15.83
▲ +0.14 (0.89%)

This chart shows the closing price for GNGBY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Getinge AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNGBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNGBY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Getinge AB (publ) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $15.83.

This chart shows the closing price for GNGBY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Getinge AB (publ). This rating has held steady since June 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/28/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/7/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight
6/28/2023HandelsbankenUpgradeMarket Perform ➝ Outperform
6/20/2023DNB MarketsDowngradeBuy ➝ Hold
4/27/2023DNB MarketsUpgradeHold ➝ Buy
4/11/2023HandelsbankenDowngradeOutperform ➝ Market Perform
2/2/2023Pareto SecuritiesDowngradeBuy ➝ Hold
1/18/2023Morgan StanleyLower TargetOverweight ➝ OverweightSEK 274 ➝ SEK 250
1/3/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
12/30/2022DNB MarketsDowngradeBuy ➝ Hold
10/20/2022JPMorgan Chase & Co.Lower TargetNeutral ➝ NeutralSEK 331 ➝ SEK 285
10/20/2022Nordea Equity ResearchUpgradeHold ➝ Buy
10/18/2022Morgan StanleyInitiated CoverageOverweight
7/20/2022JPMorgan Chase & Co.Lower TargetNeutral ➝ NeutralSEK 344 ➝ SEK 331
6/15/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
6/15/2022Nordea Equity ResearchDowngradeBuy ➝ Hold
6/13/2022CheuvreuxDowngradeBuy ➝ HoldSEK 435 ➝ SEK 280
6/13/2022Kepler Capital MarketsDowngradeBuy ➝ HoldSEK 435 ➝ SEK 280
4/27/2022JPMorgan Chase & Co.Lower TargetOverweight ➝ OverweightSEK 430 ➝ SEK 425
3/22/2022JPMorgan Chase & Co.Boost TargetSEK 425 ➝ SEK 430
3/9/2022Jefferies Financial GroupInitiated CoverageHold
1/31/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
1/19/2022Pareto SecuritiesUpgradeHold ➝ Buy
11/15/2021JPMorgan Chase & Co.Reiterated RatingNeutral
10/28/2021Berenberg BankDowngradeBuy ➝ Hold
7/26/2021AlphaValueUpgradeReduce ➝ Buy$41.32
7/21/2021Berenberg BankReiterated RatingBuy
7/19/2021JPMorgan Chase & Co.Reiterated RatingNeutral
6/29/2021Pareto SecuritiesDowngradeBuy ➝ Hold
5/25/2021Jefferies Financial GroupInitiated CoverageBuy
4/21/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
4/13/2021DNB MarketsUpgradeHold ➝ Buy
3/11/2021SEB Equity ResearchUpgradeHold ➝ Buy
3/11/2021SEB EquitiesUpgradeHold ➝ Buy
2/10/2021Berenberg BankReiterated RatingBuy
2/1/2021JPMorgan Chase & Co.Reiterated RatingUnderweight
12/9/2020Morgan StanleyReiterated RatingEqual Weight
10/19/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
9/16/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
9/9/2020Bank of AmericaInitiated CoverageBuy
8/7/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
7/31/2020Morgan StanleyReiterated RatingEqual Weight
7/20/2020Berenberg BankReiterated RatingBuy
6/17/2020Berenberg BankReiterated RatingBuy
6/12/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
4/23/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
4/17/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
(Data available from 12/23/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Getinge AB (publ) logo
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions. The company also provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, and drainage solutions; and operating room infrastructure equipment, anesthesia, advanced patient monitoring, operating room management, and operating room integration solutions. In addition, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices; bioreactor systems, DPTE systems, Getinge isolators, terminal sterilization products, and sterilizers; and vivarium, biohazardous materials handling solutions, labware cleaning and sterilization, upstream bioprocessing, and bioreactor preparation solutions. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.
Read More

Today's Range

Now: $15.83
Low: $15.59
High: $15.83

50 Day Range

MA: $16.85
Low: $14.91
High: $20.03

52 Week Range

Now: $15.83
Low: $14.84
High: $22.85

Volume

75,181 shs

Average Volume

19,020 shs

Market Capitalization

$4.31 billion

P/E Ratio

26.83

Dividend Yield

1.53%

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Getinge AB (publ)?

The following Wall Street research analysts have issued reports on Getinge AB (publ) in the last twelve months:
View the latest analyst ratings for GNGBY.

What is the current price target for Getinge AB (publ)?

0 Wall Street analysts have set twelve-month price targets for Getinge AB (publ) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Getinge AB (publ) in the next year.
View the latest price targets for GNGBY.

What is the current consensus analyst rating for Getinge AB (publ)?

Getinge AB (publ) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GNGBY.

What other companies compete with Getinge AB (publ)?

Other companies that are similar to Getinge AB (publ) include Masimo, Integer, LivaNova, CONMED and TransMedics Group. Learn More about companies similar to Getinge AB (publ).

How do I contact Getinge AB (publ)'s investor relations team?

Getinge AB (publ)'s physical mailing address is LINDHOLMSPIREN 7A, GOTHENBURG V7, 41756. The company's listed phone number is (610) 335-0000 and its investor relations email address is [email protected]. The official website for Getinge AB (publ) is www.getinge.com. Learn More about contacing Getinge AB (publ) investor relations.